INTS vs RCL · $7.7M cap vs P/E 26, rev $16.48B
Intensity Therapeutics, Inc. Common stock (INTS) versus Royal Caribbean Cruises Ltd (RCL) — a side-by-side from cached financials, not a winner call.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
Royal Caribbean Cruises Ltd (RCL) is a travel services company listed on US.
INTS does not have a complete income-statement cache yet.
Latest reported RCL revenue for 2024-12-31 was $16.48B. Net income was $2.90B. Revenue was up 18.6% from 2023-12-31 to 2024-12-31. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
INTS currently screens at market cap $7.7M. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
Not investment advice. Open the INTS and RCL stock pages for the full models.
Not investment advice.